{
    "clinical_study": {
        "@rank": "156424", 
        "arm_group": [
            {
                "arm_group_label": "270 microg/kg rFVIIa", 
                "arm_group_type": "Active Comparator", 
                "description": "Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours"
            }, 
            {
                "arm_group_label": "3x90 microg/kg rFVIIa", 
                "arm_group_type": "Active Comparator", 
                "description": "Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the\n      pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the\n      effect of the investigated drug on the body) of rFVIIa (activated coagulation factor VII)\n      following one single injection of 270 microg/kg compared to three injections of 90 microg/kg\n      rFVIIa in patients with haemophilia."
        }, 
        "brief_title": "A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Congenital Bleeding Disorder", 
            "Haemophilia A", 
            "Haemophilia A With Inhibitors", 
            "Haemophilia B", 
            "Haemophilia B With Inhibitors"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blood Coagulation Disorders", 
                "Hemostatic Disorders", 
                "Hemorrhagic Disorders", 
                "Hemophilia B", 
                "Hemophilia A", 
                "Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained before any trial-related activities. Trial-related\n             activities are any procedures that are carried out as part of the trial, including\n             activities to determine suitability for the trial\n\n          -  Male patients with confirmed diagnosis of severe congenital haemophilia A or B\n             (higher than 1% FVIII or FIX) with or without inhibitors to coagulation factors VIII\n             or IX, based on medical records\n\n        Exclusion Criteria:\n\n          -  Congenital or acquired coagulation disorder other than congenital haemophilia A or B\n\n          -  Any clinical signs or known history of arterial thrombotic events or previous deep\n             vein thrombosis or pulmonary embolism (as defined by available medical records)\n\n          -  Use of any anticoagulant (e.g. un-fractionated or low molecular weight heparin,\n             vitamin-K antagonists, direct thrombin inhibitors or factor Xa inhibitors)\n\n          -  Bleeding prophylactic treatment or FVIII or FIX immune tolerance induction (ITI)\n             treatment during the trial period"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01949792", 
            "org_study_id": "NN7777-4086", 
            "secondary_id": [
                "2013-000040-26", 
                "U1111-1138-2521"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "270 microg/kg rFVIIa", 
                "description": "Subject will receive a single injection (i.v.) of 270 microg/kg  rFVIIa (NovoSeven\u00ae)", 
                "intervention_name": "eptacog alfa (activated)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "3x90 microg/kg rFVIIa", 
                "description": "Subject will receive 3 injections (i.v.) of 90 microg/kg rFVIIa  (NovoSeven\u00ae) over a 6 hour period (each injection will be separated by 3 hours)", 
                "intervention_name": "eptacog alfa (activated)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 21, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28046"
                }
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label Single- and Multiple-dose Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa Following i.v. Administration of One Dose of 270 Microg/kg and Three Doses of 90 Microg/kg in Patients With Haemophilia A or B With or Without Inhibitors", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Thromboelastography (TEG) parameter Maximum Thrombosis Generation (MTG;'maximum velocity')", 
            "safety_issue": "No", 
            "time_frame": "10 minutes post-dose for 270 microg/kg and 10 minutes after the first injection of 90 microg/kg"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01949792"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "TEG parameters r-time, MTG, alpha angle, and maximum amplitude (MA)", 
            "safety_issue": "No", 
            "time_frame": "Prior to and 24 hours following the administrtion of 270 \u03bcg/kg and each of the 3 administrations of 90 \u03bcg/kg"
        }, 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}